Leproust Emily M. 4
4 · Twist Bioscience Corp · Filed Mar 24, 2026
Research Summary
AI-generated summary of this filing
Twist Bioscience (TWST) CEO Emily Leproust Sells 1,742 Shares
What Happened
- Emily M. Leproust, CEO of Twist Bioscience (TWST), disposed of 1,742 shares on 2026-03-20 at $43.79 per share, for a total value of $76,276. The Form 4 lists the transaction as a sale (code S) executed in the open market or privately.
- Footnote F1 clarifies this was a mandated "sell-to-cover" to satisfy tax withholding obligations tied to the vesting of restricted stock units, meaning the sale was to cover taxes and not a discretionary trade reflecting sentiment about the company.
Key Details
- Transaction date: 2026-03-20; Price: $43.79; Shares sold: 1,742; Proceeds: $76,276
- Transaction type: Sale (S); footnote F1 = sell-to-cover for tax withholding
- Form 4 filed: 2026-03-24 (reports the 3/20 transaction)
- Shares owned after transaction: Not specified in the provided excerpt
- Other footnotes in the filing (F2–F6) describe various option vesting schedules and a past performance-option vesting (F6); they do not change that this specific sale was tax withholding-related
Context
- Sell-to-cover transactions are common when restricted stock units vest and the company or plan requires withholding taxes. These are generally considered routine administrative sales and are not a clear bearish signal about the insider's view of the company.
- For retail investors, purchases by insiders often carry more weight than mandated sales; this filing documents a routine tax-related disposal rather than a discretionary sale.
Insider Transaction Report
Form 4
Leproust Emily M.
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1]2026-03-20$43.79/sh−1,742$76,276→ 858,887 total
Holdings
- 0
Employee Stock Option (right to buy)
[F2]Exercise: $5.95Exp: 2025-09-28→ Common Stock (0 underlying) - 150,879
Employee Stock Option (right to buy)
[F3]Exercise: $8.82Exp: 2027-09-28→ Common Stock (0 underlying) - 266,539
Employee Stock Option (right to buy)
[F4]Exercise: $26.66Exp: 2028-11-18→ Common Stock (0 underlying) - 131,290
Employee Stock Option (right to buy)
[F5]Exercise: $23.33Exp: 2029-10-23→ Common Stock (0 underlying) - 64,950
Employee Stock Option (right to buy)
[F6]Exercise: $67.85From: 2022-12-19Exp: 2030-08-31→ Common Stock (64,950 underlying)
Footnotes (6)
- [F1]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- [F2]The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- [F3]The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- [F4]20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- [F5]25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- [F6]Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Signature
/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust|2026-03-24